Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
8.38
-0.90 (-9.70%)
At close: Jan 28, 2026, 4:00 PM EST
8.49
+0.11 (1.35%)
After-hours: Jan 28, 2026, 7:32 PM EST
Kyverna Therapeutics Employees
Kyverna Therapeutics had 129 employees as of September 30, 2025. The number of employees increased by 10 or 8.40% compared to the same quarter last year.
Employees
129
Change
10
Growth
8.40%
Revenue / Employee
n/a
Profits / Employee
-$1,248,000
Market Cap
478.75M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 129 | 10 | 8.40% |
| Jun 30, 2025 | 129 | 17 | 15.18% |
| Mar 31, 2025 | 119 | 19 | 19.00% |
| Dec 31, 2024 | 112 | 16 | 16.67% |
| Sep 30, 2024 | 119 | 30 | 33.71% |
| Jun 30, 2024 | 112 | 23 | 25.84% |
| Mar 31, 2024 | 100 | - | - |
| Dec 31, 2023 | 96 | - | - |
| Sep 30, 2023 | 89 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 305 |
| Lyell Immunopharma | 300 |
| Prothena Corporation | 163 |
| Niagen Bioscience | 104 |
| Solid Biosciences | 100 |
| Ocugen | 95 |
| Verastem | 78 |
| Zevra Therapeutics | 59 |
KYTX News
- 16 days ago - Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference - GlobeNewsWire
- 23 days ago - Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies - Seeking Alpha
- 6 weeks ago - Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript - Seeking Alpha
- 6 weeks ago - Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock - GlobeNewsWire
- 6 weeks ago - Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA Filing - Seeking Alpha
- 6 weeks ago - Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 6 weeks ago - Kyverna Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire